title: Vaccine with beta-defensin 2-transduced leukemic cells activates innate and adaptive immunity to elicit potent antileukemia responses.
abstract: Murine beta-defensin 2 (MBD2) is a small antimicrobial peptide of the innate immune system. Recent study showed that MBD2 could not only recruit immature dendritic cells but also activate them by Toll-like receptor 4 and thus may provide a critical link between the innate immune system and the adaptive immune response. In this report, we examined the antileukemia activity of MBD2 in a murine model of acute lymphoid leukemia (ALL) L1210. L1210 cells were engineered to secrete biologically functional MBD2. MBD2-modified L1210 (L1210-MBD2) showed significantly reduced leukemogenecity, resulting in a 80% rate of complete leukemia rejection. Inoculation of mice with L1210-MBD2 induced enhanced CTL and natural killer (NK) activity and augmented interleukin-12 and IFN-gamma production. All the recovered mice from the inoculation showed a protective immunity to the following challenge with parental L1210 cells and generate leukemia-specific memory CTL. Vaccines with irradiated L1210-MBD2 cells could cure 50% leukemia-bearing mice. Depletion of CD8+ T cells but not CD4+ T cells completely abrogated the antileukemia activity of MBD2. Interestingly, NK cells were also required for the MBD2-mediated antileukemia response, although ALL generally display a high degree of resistance to NK-mediated lysis. Our results suggest that MBD2 can activate both innate and adaptive immunity to generate potent antileukemia response, and MBD2 immunotherapy warrants further evaluation as a potential treatment for ALL.
authors.affiliation: National Laboratory of Experimental Hematology, Institute of Hematology, Chinese Academy of Medical Sciences, Peking Union Medical College, 288 Nanjing Road, Tianjin 300-020, China. ma_xt@yahoo.com.cn
authors.forename: Xiao-Tong
authors.initials: XT
authors.lastname: Ma
authors.forename: Bin
authors.initials: B
authors.lastname: Xu
authors.forename: Li-Li
authors.initials: LL
authors.lastname: An
authors.forename: Cheng-Ya
authors.initials: CY
authors.lastname: Dong
authors.forename: Yong-Min
authors.initials: YM
authors.lastname: Lin
authors.forename: Yang
authors.initials: Y
authors.lastname: Shi
authors.forename: Ke-Fu
authors.initials: KF
authors.lastname: Wu
mesh_terms: D000208:Acute Disease; D000818:Animals; D000917:Antibody Formation; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D019496:Cancer Vaccines / Q000276:immunology*; D003713:Dendritic Cells; D005260:Female; D007113:Immunity, Innate; D007156:Immunologic Memory; D007694:Killer Cells, Natural; D007945:Leukemia, Lymphoid / Q000276:immunology* / Q000628:therapy*; D051379:Mice; D014161:Transduction, Genetic; D023083:beta-Defensins / Q000276:immunology*
chemical_list: D019496:Cancer Vaccines; C106641:DEFB4A protein, human; D023083:beta-Defensins